Paper12372957
Tranilast slows the progression of advanced diabetic nephropathy.
Soma J and 4 others. Nephron, 2002. Cited by 50 papers, by iCite.
Cite this record
ConductScience Library. Tranilast slows the progression of advanced diabetic nephropathy. Papers, record 12372957. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12372957
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Inflammatory Agents, Non-Steroidal | Major topic |
| Diabetic Nephropathies | Major topic |
| ortho-Aminobenzoates | Major topic |
| Adult | |
| Aged | |
| Collagen Type IV | |
| Creatinine | |
| Diabetes Mellitus, Type 2 | |
| Disease Progression | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Proteinuria | |
| Treatment Outcome |
Source PubMed
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42292355 | NLR inflammasome pathways: key targets for pathogenesis and therapy of metabolic diseases. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292355 | PubMed |
| 40415299 | The NLRP3-P2X7 Axis and Cytokine Crosstalk in Alzheimer's Disease: Mechanisms, Implications, and Therapeutic Opportunities. | CNS Neurol Disord Drug Targets | 2025 | https://conductscience.org/library/papers/40415299 | PubMed |
| 37211853 | To Explore the Putative Molecular Targets of Diabetic Nephropathy and their Inhibition Utilizing Potential Phytocompounds. | Curr Med Chem | 2024 | https://conductscience.org/library/papers/37211853 | PubMed |
| 36960868 | Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review). | Int J Mol Med | 2023 | https://conductscience.org/library/papers/36960868 | PubMed |
| 36142794 | Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36142794 | PubMed |
| 27558558 | Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. | Am J Physiol Renal Physiol | 2017 | https://conductscience.org/library/papers/27558558 | PubMed |
| 26847481 | Hypoxia: The Force that Drives Chronic Kidney Disease. | Clin Med Res | 2016 | https://conductscience.org/library/papers/26847481 | PubMed |
| 26421309 | Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy. | J Diabetes Res | 2015 | https://conductscience.org/library/papers/26421309 | PubMed |
| 25972814 | HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease. | Front Physiol | 2015 | https://conductscience.org/library/papers/25972814 | PubMed |
| 25884585 | Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats. | Diagn Pathol | 2015 | https://conductscience.org/library/papers/25884585 | PubMed |
| 24662433 | Novel targets of antifibrotic and anti-inflammatory treatment in CKD. | Nat Rev Nephrol | 2014 | https://conductscience.org/library/papers/24662433 | PubMed |
| 23179685 | Molecular targets for treatment of kidney fibrosis. | J Mol Med (Berl) | 2013 | https://conductscience.org/library/papers/23179685 | PubMed |
| 23071743 | A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat. | PLoS One | 2012 | https://conductscience.org/library/papers/23071743 | PubMed |
| 22566893 | Different roles of mast cells in obesity and diabetes: lessons from experimental animals and humans. | Front Immunol | 2012 | https://conductscience.org/library/papers/22566893 | PubMed |
| 22278738 | Tranilast ameliorates impaired hepatic functions in Schistosoma mansoni-infected mice. | Inflammopharmacology | 2012 | https://conductscience.org/library/papers/22278738 | PubMed |
| 22073152 | Predicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysis. | PLoS One | 2011 | https://conductscience.org/library/papers/22073152 | PubMed |
| 21782136 | Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. | Adv Chronic Kidney Dis | 2011 | https://conductscience.org/library/papers/21782136 | PubMed |
| 21659774 | Antifibrotic treatment and other new strategies for improving renal outcomes. | Contrib Nephrol | 2011 | https://conductscience.org/library/papers/21659774 | PubMed |
| 19455178 | Emerging therapies for chronic kidney disease: what is their role? | Nat Rev Nephrol | 2009 | https://conductscience.org/library/papers/19455178 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
| UPP1 | 7378 | PubTator's text mining | https://conductscience.org/library/genes/7378 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12372957
GET https://conductscience.org/api/papers/v1/12372957/authors